David Lebwohl, MD, EVP, CMO of Intellia Therapeutics, shares an update on Intellia’s gene editing programs, his approach to educate stakeholders on new modalities and advice for CMOs in cell & gene therapy.
Lead Editorial

David Lebwohl, MD, EVP, CMO of Intellia Therapeutics, shares an update on Intellia’s gene editing programs, his approach to educate stakeholders on new modalities and advice for CMOs in cell & gene therapy.